ReviewAntibiotics (Basel, Switzerland)2020
Carbapenem-Sparing Strategies for ESBL Producers: When and How.
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06422533 (Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia Due to Enterobacteriaceae and Pseudomonas Aeruginosa in Hemato-oncological Patients With Severe Neutropenia and Fever), which is not on this map. Cited by 88 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia Due to Enterobacteriaceae and Pseudomonas Aeruginosa in Hemato-oncological Patients With Severe Neutropenia and Fever: Non-inferiority Study
Who cites it
88 citing papers in PubMed, 3 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- Extended-spectrum β-lactamase production and antimicrobial resistance among Enterobacteriaceae causing clinical infections in Africa: a systematic review and meta-analysis (2012-2020).European journal of medical research · 2025Pooled it
- Predictors of mortality from extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia.Emerging microbes & infections · 2023Pooled it
- Association between a carbapenem post-prescription audit and gram-negative susceptibility: a 6-year time-series analysis.Archives of microbiology · 2026Article
- Risk-Stratified Effectiveness of Cephamycins Versus Carbapenems for ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026Review
- Carbapenem-Sparing Antimicrobial Stewardship in Internal Medicine: A Prospective Quasi-Experimental Before-and-After Pilot Implementation Study.Antibiotics (Basel, Switzerland) · 2026Article
- Comparison of Ceftolozane-Tazobactam Versus Meropenem Regimens in Treating Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-ProducingJournal of clinical medicine · 2026Article
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Klebsiella pneumoniae in humans, animals and the environment in Northwest Amhara, Ethiopia.Scientific reports · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Escherichia coli from patients, cattle, and environmental sources in northwest Amhara, Ethiopia: a one health approach.BMC microbiology · 2026Article
- Large Language Model Recommendations for Empiric Antibiotics Versus Clinician Prescribing: A Non-Interventional Paired Retrospective Antimicrobial Stewardship Analysis.Antibiotics (Basel, Switzerland) · 2026Article
- Recurrent infections caused by ESBL-producing enterobacterales with or without subsequent development of distinct carbapenem-resistant phenotypes: differential driving factors and impact on outcome.JAC-antimicrobial resistance · 2026Article
- Multidrug-Resistant Pathogen Clonal Spread in Nigeria: A Systematic Review and Meta-Analysis.Health science reports · 2026Review
- Antimicrobial resistance profile and molecular analysis of virulence among Escherichia coli isolated from pregnant women with asymptomatic bacteriuria in Gorgan, Iran.BMC pregnancy and childbirth · 2026Article
- Etiopathogenesis and Antibacterial Therapy Approach in Patients with Acute Obstructive Pyelonephritis-A Retrospective Study.Antibiotics (Basel, Switzerland) · 2026Article
- Population structure, antimicrobial resistance, and virulence factors of diabetic foot-associatedMicrobiology spectrum · 2026Article
- Personalized Approaches to Patients with Intra-Abdominal Infections.Journal of clinical medicine · 2025Review
- Effect of Empirical Antimicrobial Therapy of Piperacillin-tazobactam Versus Carbapenems on Mortality for Patients with Sepsis from Nursing Homes.Internal medicine (Tokyo, Japan) · 2025Article
- ESBL-ProducingMicroorganisms · 2025Article
- Molecular Characterization of Escherichia coli Causing Community-Acquired Urinary Tract Infections in a Suburban Area in West Bengal, India: Dispersal of Multidrug-Resistant Epidemic ST131 Clone Carrying CTX-M-1.Current microbiology · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and correlated with hospital infections, but they have been evolving as an increasing cause of community acquired infections. The spread of ESBL constitutes a major threat for public health, and infections with ESBL-producing organisms have been associated with poor outcomes. Established therapeutic options for severe infections caused by ESBL-producing organisms are considered the carbapenems. However, under the pressure of carbapenem overuse and the emergence of resistance, carbapenem-sparing strategies have been implemented. The administration of carbapenem-sparing antibiotics for the treatment of ESBL infections has yielded conflicting results. Herein, the current available knowledge regarding carbapenem-sparing strategies for ESBL producers is reviewed, and the optimal conditions for the "when and how" of carbapenem-sparing agents is discussed. An important point of the review focuses on piperacillin-tazobactam as the agent arousing the most debate. The most available data regarding non-carbapenem β-lactams (i.e., ceftolozane-tazobactam, ceftazidime-avibactam, temocillin, cephamycins and cefepime) are also thoroughly presented as well as non β-lactams (i.e., aminoglycosides, quinolones, tigecycline, eravacycline and fosfomycin).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.